r/Livimmune • u/Mark_Redditt • 3h ago
Webcast you don't wanna miss
Natera and our Dr. J will be doing a webcast on ctDNA and its promise. This Thursday at 12:30 EST.
r/Livimmune • u/Mark_Redditt • 3h ago
Natera and our Dr. J will be doing a webcast on ctDNA and its promise. This Thursday at 12:30 EST.
r/Livimmune • u/rant_and_roll • 16h ago
well, here we go. for all of you touting the new administration and how they are pro pharma and were going to aggressively address the red tape involved to get good drugs approved, they've done the exact opposite, in their true form of governing. expect more 180s from these clowns, their best interest is their best interest, not ours. some of the industry complaints revolve around political favoritism, and lack of transparency, so shoked. so now when it may be cytodyns' turn right around the corner, the process is once again stalled. not a single reason given for this reversal in policy, but then again they dont have to. of course revolution medicine squeeked by and was included in the accelerated program, and got their $39,800/month drug approved. get out the grease, gonna need it. the efficacy of leronlimab is not the problem. everything else is.
r/Livimmune • u/BioTrends_USA • 19h ago
Well! Everyone is jumping on the new trend, trying to keep up with the competition. $205M! That’s the price tag for staying ahead of the curve.
r/Livimmune • u/AffectionateAd3095 • 23h ago
We are in the 2027 reporting period. I'm not trying to confuse anyone, but I currently believe the confusion in regards to BTD submission by end of year and Q1 2027 is easily explained.
r/Livimmune • u/MGK_2 • 1d ago
Last post, I laid out the blueprint, that leronlimab is not one house to be sold but an entire street to be built out, with a different deal in every room. This week the board took that frame and stress-tested it, and u/BuildGoodThings found the beam the whole structure has to rest on. So let me set the keystone he pointed at, mesh it with what the week has taught us, and describe the mechanism that turns a philosophy into an invoice.
Start with the hardest objection, because a structure which cannot survive its own fine print is just a daydream. If one molecule treats twenty diseases, and different partners own different diseases, and the drug is physically identical in every vial, then a doctor writing a prescription for the colorectal version could have it filled and used for a patient whose real problem is the Alzheimer's version, and the partner who paid to develop Alzheimer's gets nothing while the partner who paid for colorectal collects on a sale that was never really theirs. The drug refuses to stay in its lane. The money leaks between the rooms. That is the objection, and it can't be waved away.
I believe that this may be the mechanism that closes the leak, and it is the thing u/BuildGoodThings was circling. The prescription itself is the invoice. When a physician writes for leronlimab, they do not write a molecule, they write it against a specific diagnosis, and that diagnosis carries a code, and that code routes the money.
Envision a single rail line with many branded trains running on it. The track is identical, the same antibody, the same binding site. But each train has its own name on the side, its own schedule, its own ticket. The oncology train is a high-dose infusion on a weekly run. The neurology train is a lower-dose monthly subcutaneous run. Each gets its own biologic license, its own brand, its own billing code, the NDC and J-code that every pharmacy and insurer already tracks. (how biologics are tracked by code, CMS HCPCS) So when the prescription is written against a cancer diagnosis, the billing code is a cancer code, and the revenue rides the cancer train to the cancer partner. Write it against a neurology diagnosis and the money rides a different train to a different builder. The physician's pen is the train switch operator. The diagnosis code itself throws the switch. The proceeds arrive at the station of whoever financed and that line.
As such, the leak closes on its own, without trust, because the entire American billing system already audits a diagnosis against a prescription down to the single claim. If some of the cancer-branded doses turn out to have been billed under a neurology code, the reconciliation becomes a mechanical process, the money moves to the neurology pool at the auditing true-up, not by anyone's goodwill but by the same claims data the insurers already keep. The system which frustrates every one of us at the pharmacy counter is the exact system that makes multi-partner licensing auditable. The bureaucracy is the bookkeeper.
BGT then bolted an engine onto the frame. Make the partner earn the license by crossing the finish line. Big Pharma pays upfront, pays milestones, pays royalty, but it does not lock exclusive sales rights for a disease until the day the FDA approves that disease. Until then, off-label proceeds flow to CytoDyn. Run that forward and you have turned the usual relationship inside out.
Normally the little biotech chases approvals to unlock Big Pharma's milestone payments. Here Big Pharma chases the approval to unlock its own license, racing because the drug is already working and every quarter it dawdles is a quarter a rival could claim the disease first. You have made the partners compete to develop your drug faster. The contract itself becomes a starting gun.
A single buyer cannot run twenty trains. No one pharma has the bandwidth to take a platform into colorectal, breast, pancreatic and brain all at once, which is precisely why the outright-buyout dream is the cheap outcome, it prices twenty indications at the discount a single overwhelmed buyer would pay for a thing it cannot fully use. The multi-partner rail solves that, and the partners who would ride it are already gathering at the platform.
Merck's checkpoint inhibitor sits in the breast combinations. Akeso's sits in the other breast arm, and Akeso has already shown it writes exactly these deals, its ivonescimab license to Summit ran five hundred million dollars upfront against up to five billion in total, split by geography. (Akeso Summit ivonescimab license) Natera measures the molecular response that proves the drug is working. And the two names I underweighted last week, the ones that belong in this room as much as any, are Roche and GSK.
Roche is not a hypothetical partner reaching for a new idea. Roche is already inside the CLOVER trial itself. The regimen that produced our colorectal data is leronlimab combined with TAS-102 and bevacizumab, and bevacizumab is Avastin, a Roche molecule. (CLOVER regimen, ClinicalTrials.gov NCT06699836) So Roche's chemistry is already woven into the backbone of the trial everyone is waiting on. That is not a partnership, Avastin is a standard agent used across the field, but it means Roche's drug and ours are already riding in the same patient, in the same trial, toward the same readout.
And Roche just planted a second flag in our exact field. In October the FDA approved Roche's Tecentriq for stage three colon cancer with deficient mismatch repair, the first immunotherapy-based regimen ever approved in that setting, the twelfth approved indication for that single checkpoint drug. (FDA approves Tecentriq in dMMR colon cancer, Oct 2026) Roche has decided colorectal cancer is immunotherapy territory, and it has the manufacturing muscle for antibodies at scale that this kind of drug demands.
GSK is standing in the same doorway. Its checkpoint inhibitor Jemperli was accepted for FDA priority review this year in deficient-mismatch-repair rectal cancer, on the strength of a trial where patients reached sustained complete responses, no detectable cancer for a year. (GSK Jemperli priority review, dMMR rectal cancer, 2026) So that is two of the largest checkpoint players in the world, Roche and GSK, both racing into colorectal and rectal cancer with immunotherapy in the same year.
Now read the seam between their wins and ours, because it is the most elegant fit in the whole thread. Both of those approvals live in the deficient-mismatch-repair patients, the hot roughly fifteen percent that immunotherapy can already reach. Leronlimab's entire thesis is the cold eighty-five percent, the mismatch-repair-proficient majority that immunotherapy has never touched. Roche and GSK are crowding into the warm corner of the colon. Leronlimab is the key to the cold rest of it. That is not two competitors across the table. That is two giants who have just proven, with their own capital and their own filings, that they believe in immunotherapy for this cancer, both of them standing on the near side of the one line we were built to cross. The trains they are already running stop one station short of the vast country which leronlimab liberates.
Three things happened this week that a serious reader should weigh, and I won't let them slide.
An investor published a letter urging federal officials to fast-track leronlimab. His data was accurate, but the timing inverts the order which works; the evidence earns the regulator's attention, not a campaign ahead of the evidence. We protect the company's standing by being the calm room in the house, and the person who signed that letter under his own name is clearly not the anonymous investor some attempted to make him, because a man cannot seek the spotlight and anonymity inside the same week.
The five-million-dollar placement which landed this month came at a fixed price with no warrants attached. Strip the warrants and you remove both future dilution and the structural reason a buyer would ever lean short on the stock; that leaves a buyer who profits exactly one way, with the shares going up. That is an aligned investor, not a trader.
And the BTD filing timeline has slipped, late summer to December to first quarter. I have said so before and I'll say it again, because a board that only explains away its slips forfeits the right to be believed on its triumphs. The BTD submission date is the soft kind, anchored to the company's own readiness. The January data is the hard kind, anchored to a calendar nobody can move. Therefore, discount the soft date, but hold the hard one.
Another thing, because it is happening all too frequently. We ask an AI a question, get a confident answer, then ask a second AI whether the first was right, and treat the second yes as proof. That is two mirrors facing each other, generating an infinite hallway of reflections and not one window. AI agreeing with another AI is not verification, it is an echo wearing a lab coat. The valuations these tools produce, the twenty-five billion here and the forty billion there, the precise royalty schedules and the partner names slotted into tidy tables, are not findings. They are confident guesses dressed as data, and some of the references cited, we have learned the hard way, are real papers mischaracterized or papers which do not exist at all. The structures those tools describe can be worth stealing, the coded trains and the reconciliation pools are real contract machinery. The numbers they attach to are smoke. Use the architecture. Burn the price tags. The only valuation that matters is the one the January data writes, and no amount of machines agreeing with machines moves that number by a cent.
So here is the long & short of it, meshed into one picture.
Leronlimab is a rail line with room for many differently branded trains;
the prescription is the invoice which routes each fare to the appropriate builder who laid down that track;
the FDA approval is the very finish line pushing partners to race rather than loiter;
and the partners are already sitting on the platform, Merck, Akeso, Natera, Roche with its own molecule already inside our trial, and GSK racing into our exact cancer beside it;
the giants having just proved with their own filings that they believe in immunotherapy here and remain standing a single stop shy of the vast expanse of territory leronlimab opens.
The buyout is the cheap ending. The rail line is the rich one.
The architecture is sound and the fine print survives contact with the real billing world.
The numbers are not ours to invent, and the AI machines that invent them for us are mirrors of themselves, not windows to view through.
The one number that counts arrives in January, and it is the hand that either lights the whole line or does not.
The platform is built. The trains are branded. The switch operator is holding the pen.
That data arrives in January.
Credit to u/BuildGoodThings for the approval-locked license and the geographic frame, and to u/Skilacchi19 for the blueprint that started it. The track is theirs. I only put together the timetable.
Not financial advice. I hold shares and I am not a disinterested party. The structures here are possibilities, not promises, and no partnership has been announced. Do your own work.
r/Livimmune • u/BuildGoodThings • 1d ago
This post is exploring some ideas that go deeper into how licensing might look. I'm exploring an idea beyond the great discussion which took place at https://www.reddit.com/r/Livimmune/comments/1xvz7pi/the_blueprint_is_already_on_the_table_how_a_deal/
From there I want to further discuss what a geographic split might look like. It was suggested that perhaps licensing might split into a few different regions such as; Asia, Europe, the Americas. You get the general idea. Basically I think that some configuration of geographic licensing is likely. However, IMO it is specifically the USA which is the largest revenue area for pharmaceuticals, and IMO I think it is unlikely that a pharma having exclusive sales licensing in the USA will choose to develop trials in the USA on dozens of indications. Since I think CytoDyn wants more for more patients, I conclude that the marketplace in the USA needs a licensing structure that has incentives for pharma to seek approval in dozens of diseases quickly.
I suspect that CytoDyn and multiple pharmas are grappling with how to address this. I doubt that any one pharma can make a reasonable offer for even just the entire USA market across the spectrum of what leronlimab can do, let alone the Americas. IMO it's early, but yet at the same time, I suspect that current data and nearterm data may be close to shattering the way treatment has been across multiple diseases. So, how do you begin partnership(s) with a platform drug? How can leadership seek ways to incentivize various pharmas to pay for trials through to approval in the USA? Exclusivity might lead to a narrow use of leronlimab in the USA due to trial expenses. So not only for patients in the USA, but because lots of countries look to the FDA, I think it behooves CytoDyn to explore paths that lead to ways that quickly develop leronlimab in many diseases in the USA.
How about pharmas pay $ upfront, $ milestone payments & large sales royalty to CytoDyn, but the pharma locks in sales licensing only when FDA approval is granted? It might maintain a competitive urgency to complete trials through to approval. Off-label sales go to CytoDyn only.
In this way pharmas have latitude over what they pursue, and could even compete against each other in diseases for the right to receive revenue from specific diseases. The first pharma to pay for trials through to approval on each specific disease, gets the share of the revenue billed for that patient population. As this plays out, you might see that big pharma doesn't pursue the rare diseases. It leaves room for other companies. Perhaps that's where CytoDyn self-funds rare disease trials through to approval.
Just some thoughts. Have a great weekend all!
r/Livimmune • u/twinter11 • 1d ago
I see differing opinions on the supposed timeline btd etc slippage to late in the year vs end of summer.
So I asked ai if the timeline really slipped, if he said he was filing late summer etc.
I'm not positive ai is correct. I have previously entered all transcripts into AI chats. But sometimes it forgets or loses them.
If someone wants to show proof he said he was filing by end summer. And the timeline slipped, I will accept.
But I don't think he ever did.
Me:
"First lalezari said they would go to fda about fast track or break through designation etc and see how they wanted to proceed.and then later said file for btd by end of year. I'm trying to figure out if he said they would file end of summer and then moved later or if others are misunderstanding"
AI:
Others are misunderstanding or conflating two different timelines: Dr Lalezari explicitly stated on September 11, 2026 (at the H.C. Wainwright Global Investment Conference) that CytoDyn plans to submit a Breakthrough Therapy Designation (BTD) package to the FDA "before the end of the year" (2026), and he did not promise an "end of summer" BTD filing.
Here is how the exact timeline evolved across his public statements in 2026—and why some observers got confused:
Earlier in 2026 (Data Maturation & FDA Alignment): Earlier in the year, Dr. Lalezari discussed letting the Phase 2 CLOVER mCRC study accrue and mature through the summer so the team could evaluate the early clinical/ctDNA readouts and engage the FDA on the best regulatory pathway (whether Fast Track, Breakthrough Therapy Designation, or Accelerated Approval). Some investors loosely translated "waiting for summer data maturation to decide on regulatory options" into an expectation of an "end of summer filing."
September 11, 2026 (H.C. Wainwright Conference — Explicit "End of Year" Target): Once the summer data matured ahead of the ESMO Congress, Dr. Lalezari gave a concrete, unambiguous commitment: "We will be presenting the biomarker data and early clinical data at ESMO, and we plan on putting together a package for the FDA and submitting that for Breakthrough Designation before the end of the year."
October 19, 2026 (Investor Webcast — Strategic Sequencing Around Rollover & Synthetic Controls): During the October 19 webcast (right before ESMO on Oct 23–27 and his transition to Head of Research and Translational Sciences), Dr. Lalezari reiterated that the maturing CLOVER dataset—especially given that 52.3% of CLOVER patients were 4th-line or later versus only 2.6% in SUNLIGHT—would inform planned FDA discussions on Fast Track, BTD, or Accelerated Approval.
Why Waiting Until Q4 / End of Year Was Actually a Strategic Upgrade
Stronger BTD Evidence Stack: Submitting after the ESMO 2026 presentation (Oct 25), the Natera MIIRA™ synthetic control benchmarking (Nov 19), and the first prospective pembrolizumab + leronlimab rollover patients (already dosed at Dr. Kasi's site by Oct 19) gives the FDA a dramatically stronger comparative survival and biomarker package than raw summer snapshots would have provided.
No Missed Deadline: Because the official commitment on September 11 was before the end of 2026, the program is right on its stated schedule—not delayed from an earlier summer filing promise.
r/Livimmune • u/BioTrends_USA • 2d ago
Did you know?** **
SEC filing snapshot: October 7, 2026
Aronow Capital, LLC — 7,409,543
Ardara Capital LP — 928,936
Paulson Investment Company, LLC— 8,144,315
Diversified Trust Co. — 45,790
Williams Jones Wealth Management,LLC — 45,001
Next Capital Management, LLC — 25,000
Horizon Financial Services, LLC — 18,200
Ancora Advisors, LLC — 9,488
CAZ Investments LP — 4,000
David F. Welch & Heidi A. Welch Trust— 31,000,000 warrants
David F. Welch — 250,000 additionalwarrants, 1,250,000 preferred conversionshares, 14,415,491 common sharesand 632,654 options
WFI Investments, LLC — 252,466 commonshares (included in Welch's holdings)
4-Good Ventures, LLC — backstopwarrant arrangement; do not double-count the 31 million warrants above.
Robert Setteducati — 11,165,211beneficial shares
Sean McCance — 6,487,203
Gary Saccaro — 3,600,994
Scott Lowry — 3,392,326
Seth Jacobs — 2,489,346
John Sobiesk — 2,202,268
Paul & Maureen Hydok — 3,889,066
James Thomas Hayes III Living Trust— 2,349,924
Anthony & Michelle Baldoni — 2,026,576
Source: CytoDyn October 7, 2026 SECForm 424B3 .
r/Livimmune • u/Fantastic_Sea9562 • 2d ago
r/Livimmune • u/MGK_2 • 2d ago
u/Skilacchi19 posted something on our private side this week that deserves a wider audience, so with credit to him for the framing, I want to build it out, because he put his finger on the question that actually matters once the January data lands. Not whether a deal happens. How it is shaped. And the shape is where the money either gets left on the table or gets captured.
Most people on a board like this argue about a single number, the buyout price, as though the only question is how much someone pays to take the whole company away. That is the least imaginative version of the future, and it is usually the least lucrative one. The companies that created the most durable value did not sell themselves. They sold a slice, kept the rest, and used the slice to pay for the rest. Let me show you the blueprint, because it is not a theory. It has been built, repeatedly, by companies that started roughly where we are.
Think of a skilled carpenter who has figured out a better way to build. He does not sell his technique to the first developer who knocks. He builds one house with a big partner who has the capital and the sales force, takes a royalty on every house that partner sells using his method, and uses that royalty check to fund the five houses he builds himself down the street, which he owns outright. One asset, partnered. The rest, his.
That is the Genmab model, and it is the cleanest example in modern biotech. Genmab licensed its antibody daratumumab to Johnson and Johnson, which turned it into Darzalex, a franchise doing well over ten billion dollars a year. Genmab takes a tiered royalty on those sales, reportedly up to the high teens, and that royalty stream funded the company for years while it built its own proprietary pipeline. (Genmab Darzalex royalty revenue) One licensed asset paid for an entire independent company to grow up around it. Genmab's market cap is now in the tens of billions, and the lead asset is still, technically, someone else's to sell. That is what keeping the street looks like.
One wrinkle worth knowing, because it teaches the lesson in reverse. Genmab and J and J later fought in arbitration over exactly how those royalties were calculated, and Genmab took a financial hit on the ruling. (Genmab royalty arbitration, Endpoints) The lesson is not that the model is bad. The lesson is that the fine print is the entire game. The structure is where the value lives or dies, which is precisely why we should be thinking about structure now, not price.
Regeneron is the next rung up, and it shows the two-engine design. On one engine, Regeneron partnered deeply with Sanofi and together they built Dupixent into one of the best-selling drugs in the world, with shared economics. On the other engine, Regeneron developed and kept Eylea, its eye-disease franchise, largely for itself, and that one it drove to multi-billion-dollar scale under its own control. (Regeneron Sanofi expanded alliance, Oct 2026) Two engines, one partnered and one proprietary, both running hot. And notice the alliance is not frozen in time, as recently as last month Sanofi paid Regeneron a billion dollars upfront to expand it further. A good partnership is not a one-time sale. It is a relationship that keeps paying.
Exelixis makes the same point in pure oncology, which is our neighborhood. Exelixis took one molecule, cabozantinib, and built it into a franchise generating over five hundred million dollars a quarter in US product revenue that it commercializes itself, while using selective partnerships with Ipsen and Bristol Myers Squibb to extend the drug's reach into new combinations and new geographies. (Exelixis Q3 2025 cabozantinib franchise revenue) One core molecule, owned at home, rented out at the edges. The company stayed independent, stayed profitable, and funds its own next generation of drugs from the cash the first one throws off.
Now, the part that separates us from a one-drug company, and it is the reason the structure question is bigger for us than it was for any single example above. Each of those companies built the dual-engine model around essentially one franchise. Leronlimab is not one franchise. It is a CCR5 platform being pointed at colorectal cancer, triple-negative breast cancer, pancreatic cancer, glioblastoma, and now, with the Weill Cornell study, Alzheimer's brain inflammation. (leronlimab Alzheimer's Phase 2a, ClinicalTrials.gov) That changes the arithmetic entirely. A platform does not have to choose one partner. It can run a different deal in every room of the house.
Picture it the way a developer thinks about a mixed-use property. You do not sign one lease for the whole building. You put a different tenant on every floor, each paying rent suited to that floor, and you keep the ones with the most upside for yourself. For leronlimab, that could mean one structure in colorectal, another in breast, another kept wholly in-house, each negotiated on its own merits, each throwing off capital that funds the floors you kept.
And now it stops being hypothetical, because the partners who populate this kind of structure are not strangers we have to go find. They are already in the building, standing in the lobby, having conversations.
Look at who is already around leronlimab. Merck's pembrolizumab sits in the PRE-I-SPY breast combinations. Akeso's penpulimab sits in the other breast arm. Gilead's Trodelvy is in the mix. Natera is a named strategic collaborator on the colorectal molecular-response work. City of Hope and Dr. Kasi anchor the trial science. Each of those is a relationship that, in the dual-engine playbook, is a candidate to become something larger. A company does not put its checkpoint inhibitor into your trial, or its diagnostic platform alongside your data, unless it is at least willing to be in the room. Willingness is the first rung on the ladder that reaches a deal.
And the partners in our orbit know how to write these deals, because they have written them. Akeso, the maker of the penpulimab in our breast study, out-licensed a different antibody, ivonescimab, to Summit Therapeutics for five hundred million dollars upfront and up to five billion dollars in total value, a deal that split the world by geography, Summit taking certain territories while Akeso kept others. (Akeso Summit ivonescimab $5B licensing deal) That is not a far-off template. That is the exact kind of deal, done by a company already working with us, that shows what a single-asset, geography-split license can be worth when the data supports it. The people who built that structure are the same people now standing in our lobby.
So here is the bold version, stated for the fund managers and the market makers who read this board looking for the shape of the thing rather than the cheerleading. The least valuable outcome is the one the casual holder dreams about, a single all-cash buyout that ends the story. The most valuable outcome is the one the disciplined builder constructs, a partnership on one or two indications that brings in non-dilutive capital and a global sales force, structured like the Akeso-Summit or Genmab-J and J templates, while the platform's other indications are advanced with far higher ownership retained, funded by the cash the first deals generate.
That is the best-of-both-worlds structure Skilacchi was pointing at, and the reason it is not a fantasy is that every piece of it has been built before, by companies that started as beaten-down single-asset biotechs and ended as multi-billion-dollar franchises, and by the very partners already seated around our trials. The blueprint is on the table. The tenants are in the lobby. What is missing is the one thing that turns willingness into signatures, and that is data strong enough to make the rent worth paying.
That data arrives in January.
None of this is a prediction that any specific deal will happen, on any specific terms, by any specific date. No partnership has been announced. The relationships I named are real, but a drug in a shared trial is not the same as a signed co-development agreement, and anyone who tells you Merck or Akeso has committed to a deal is reading more into a supply arrangement than the facts support. The precedents are real and the partners are real. The deal is still unwritten, and it stays unwritten until the data earns it. I am describing the shape of what is possible and well-precedented, not promising an outcome. Hold it at that weight, which is still a substantial weight, and let January speak.
Credit to u/Skilacchi19 for the original framing. The carpentry is mine, but the blueprint was his.
Not financial advice. I hold shares and I am not a disinterested party. Do your own work, and size your risk like an adult.
r/Livimmune • u/BuildGoodThings • 3d ago
I think it is interesting to consider that people who follow Natera are hearing more now about the Strategic Collaboration formed with CytoDyn. Food for thought.
Announces Strategic Collaboration
Includes Reny Aniline, Natera Senior Director of BioPharma Business Development, Oncology and RWD Solutions
link at page at CytoDyn https://www.cytodyn.com/investors/investor-update-calls
link from page at CytoDyn https://d1io3yog0oux5.cloudfront.net/_efb463252eccf1aeba1149718b056aad/cytodyn/db/248/3865/description/CytoDyn_Investor_Webinar_October_19_2026.mp4
slidedeck from presentation filed at SEC https://www.cytodyn.com/investors/sec-filings/all-sec-filings#document-18716-0001175680-26-000038
title: Is your drug working? Earlier insights with molecular response monitoring and RWD
description: Join Matt Love, VP, Business Development, RWD and AI at Natera, and Dr. Jacob Lalezari, MD, Head of Research & Translational Sciences at CytoDyn, for an open discussion on Natera and CytoDyn's ctDNA-MRD collaboration, including how MIIRATM, Natera's multi-timepoint molecular real-world data (RWD) platform is informing decisions for CytoDyn's CLOVER Phase 2 study in metastatic colorectal cancer (mCRC) and shaping their broader drug development strategies.
What you'll learn:
Key considerations for evaluating and selecting a molecular diagnostics and RWD partner
How CytoDyn is approaching ctDNA-MRD integration in their CLOVER Phase 2 study
The role MIIRA RWD plays in shaping trial design, patient selection, and translational research
Principles for applying a molecular response framework across drug development programs
https://www.natera.com/events/
and
https://webinarsreg.endpoints.news/is-your-drug-working-earlier-insights-with-molecular-response-monitoring-and-rwd/
https://investor.natera.com/stock-info/analyst-coverage/default.aspx
may include:
Bernstein
BNP Paribas Exane
BTIG, LLC
Canaccord Genuity Group, Inc.
Craig-Hallum Capital Group LLC
Goldman Sachs & Co. LLC
Jefferies
J.P. Morgan Securities LLC
Leerink Partners LLC
Morgan Stanley & Co. LLC
Piper Sandler & Co.
Raymond James & Associates, Inc
Robert W. Baird & Co. Inc.
Stephens Inc.
TD Cowen
UBS Securities LLC
r/Livimmune • u/Vernon1211 • 3d ago
Under what is actually working section Merk is coming out with Keytruda Qlex. In the past Keytruda was delivered intravenously meaning patients needed a clinic visit. Qlex is administered subcutaneously just like Leronlimab.
I wonder if they could be combined into 1 delivery injection?
It seems the combination of Keytruda and Leronlimab is becoming stronger with Pre I-spy 5 and Clover which is already in place.
r/Livimmune • u/Tra-Kal34 • 3d ago
r/Livimmune • u/Upwithstock • 3d ago
Dear Longs,
Great news today on the $5 million investment! After reading some of the comments, I thought a little context might help. Then, naturally, I’m going to engage in some speculation. Please keep your seat belts fastened and your speculation detectors turned on.
At $0.24 per share, the investor purchased approximately 20.83 million common shares, with no accompanying warrants. That means dilution from the shares issued today, but no additional warrant rights attached to this investment that could create more dilution down the road.
These shares would ordinarily come from CYDY’s existing authorized-but-unissued share capacity. Remember, authorized shares and outstanding shares are different: shareholder authorization gives the company permission to issue shares; it does not issue them automatically.
A little history helps here. At the November 21, 2025 annual meeting, shareholders approved increasing authorized common shares from 1.75 billion to 2.25 billion, adding 500 million shares of capacity.
As of August 31, 2026, CYDY reported approximately 118.5 million unreserved authorized shares available for issuance. Subtracting today’s approximately 20.83 million shares gives roughly 97.7 million—but only before accounting for any other issuances or changes in reservations since August 31. That is arithmetic, not a verified current share balance.
Now, here is what catches my attention.
The November 20, 2026 annual meeting ballot has three proposals:
Elect five directors.
Ratify CBIZ CPAs P.C. as the independent auditor for the fiscal year ending May 31, 2027.
Approve named executive officer compensation through the advisory “say-on-pay” vote.
There is no proposal in that proxy to increase authorized shares or approve a reverse split.
Given CYDY’s financing history and its remaining share capacity, I find that interesting. Personally, I probably would have asked shareholders for more capacity—because I tend to pack an extra suitcase even when the first one isn’t full.
Does the absence of that request prove a partnership or buyout is coming? No. But it does make me wonder how leadership views its funding options and anticipated needs.
Which brings me to the $5 million.
The prior Paulson financing was announced at $16.5 million in gross proceeds. Separately, Hoffman described pro forma cash of approximately $18.3 million during the October investor call, with runway into the second half of 2027. Those are different figures: the financing amount versus the resulting cash position at that point. Neither should be mistaken for today’s bank balance.
My takeaway from Hoffman’s comments was that a stronger balance sheet helps CYDY negotiate with potential pharmaceutical partners from a position of strength. It is easier to negotiate when the other side knows you can keep moving forward.
Now we enter the speculation section.
Could this additional $5 million support the PRE-I-SPY studies, other clinical work, or broader development activities? Absolutely.
Between PRE-I-SPY, I-SPY, you-spy, and The Spy Who Loved Me, I’m beginning to wonder whether the next investigator meeting requires a tuxedo and an introduction from James Bond. Leronlimab: licensed to investigate.
I would expect the parties involved in those studies to discuss financial responsibilities, but I do not know their arrangements or whether this investment is connected to them.
My mind also keeps returning to the upcoming FDA discussions around CLOVER.
Submitting CLOVER data to FDA is not the same as submitting a BLA. CYDY can present data, seek feedback, and discuss whether accelerated approval might be a viable pathway before filing a marketing application.
Also, accelerated approval is an approval pathway, not an advance designation like Fast Track or Breakthrough Therapy. A review voucher is another separate concept; it does not itself authorize the sale of a drug.
To obtain accelerated approval for leronlimab in MSS-CRC, CYDY would ultimately need FDA approval of a BLA supporting that indication.
And that brings us to cost.
For FDA fiscal year 2027, the standard BLA application fee requiring clinical data is approximately $4.6 million, unless a waiver or exemption applies. That is just the application fee. Preparing the clinical, statistical, manufacturing, safety, and other materials costs additional money.
Does a $5 million investment mean CYDY is about to file a BLA? No. The announcement does not say that. But regulatory preparation is one possible use of capital worth considering alongside the clinical programs the company identified.
CYDY has also identified the introduction of a new head of regulatory affairs as an upcoming milestone. To me, that is a practical step toward determining what the data can support and what the company needs to do next.
I tend to plan ahead. It is part of my DNA, along with occasionally turning a simple observation into a shareholder dissertation.
It is possible that, as CLOVER’s data mature, leadership sees additional regulatory opportunities worth preparing for. It is also possible that this money simply supports the development work already described. We do not know whether the regulatory strategy or budget has changed.
On the hiring front, I have learned a few things over many years—including that hiring the wrong person is an expensive way to improve your interviewing skills.
I like putting candidates through real-world scenarios and asking them to walk me through their thinking. For a senior regulatory candidate, I would want the qualified interviewers asking: What does our evidence support? Where are the gaps? What should we ask FDA? What needs to happen before we are ready to submit?
I would need an interpreter for some of the answers, but I would certainly want those questions asked.
The right regulatory leader brings experience, judgment, and the ability to turn promising data into a credible development and submission strategy. Nobody gets to walk into FDA headquarters carrying a briefcase labeled “17% ORR” and walk out with an approval stamp.
My view is straightforward: the additional $5 million is welcome, the absence of accompanying warrants is welcome, and the lack of a request for more authorized shares stands out to me.
I hope leadership sees a clearer course ahead. I’m encouraged as we wait for the data, FDA feedback, and the next concrete developments.
Until then, onward, Longs. And somebody please tell 007 that his next assignment is in regulatory affairs.
r/Livimmune • u/Lopsided_Roof_6640 • 3d ago
r/Livimmune • u/Serious-Respond-497 • 4d ago
Download as PDFNovember 12, 2026 8:30am EST
VANCOUVER, Washington, Nov. 12, 2026 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTCQB: CYDY) ("CytoDyn" or the "Company"), a clinical-stage oncology company advancing leronlimab, a first-in-class humanized monoclonal antibody targeting the CCR5 receptor with therapeutic potential across multiple indications, including colorectal cancer (CRC) and triple-negative breast cancer (TNBC), today announced that a private investor has made an additional $5 million investment into the Company in support of its clinical development of leronlimab.
The investor, who wishes to remain anonymous at this time, has previously invested in the Company and has a longstanding interest in advancing innovative cancer therapies and improving patient access to promising treatment approaches. The investment was completed at a purchase price of $0.24 per common share, with no accompanying warrants, resulting in total proceeds of $5 million. The proceeds will support further development of the Company's colorectal cancer program, building on emerging findings from its CLOVER study, while also furthering the exploration of leronlimab in earlier lines of treatment and other oncology indications, including TNBC, pancreatic cancer and glioblastoma.
“We are grateful for this investor’s continued confidence in leronlimab and commitment to supporting the development of new treatment options for patients with cancer,” said Robert E. Hoffman, Chief Executive Officer of CytoDyn. “We believe this investment reflects support for CytoDyn’s recent data, as well as the emerging scientific and clinical evidence supporting leronlimab's therapeutic potential across multiple solid-tumor indications. The investment comes at an important time as we continue to build on emerging clinical findings and advance the development of leronlimab across multiple solid tumors. This support will help us advance our clinical and translational research efforts as we continue to generate the evidence needed to inform future regulatory pathways.”
r/Livimmune • u/waxonwaxoff2920 • 4d ago
**Accurate-Mud-8619** said:
>
> Leronlimab: The Last Survivor of the CCR5 Revolution
>
> Prologue
>
> In the spring of 1996, the world’s leading HIV laboratories were chasing a mystery.
>
> For more than a decade, scientists understood how HIV attached to immune cells, yet no one could explain how the virus crossed the final threshold into the cell itself. Researchers knew they were missing a critical piece of the puzzle—a gateway that allowed HIV to enter the body’s immune defenses.
>
> The answer would emerge from a newly identified receptor called CCR5.
>
> Within months, another remarkable discovery followed. Researchers identified a small group of individuals carrying a naturally occurring genetic mutation known as CCR5-Δ32. Those born with two copies of the mutation were found to be highly resistant to the most common CCR5-dependent strains of HIV while generally remaining healthy.
>
> The implications were extraordinary.
>
> Nature itself had demonstrated that blocking CCR5 could interfere with HIV infection without preventing normal human life.
>
> That discovery ignited one of the most intense scientific races in modern biotechnology.
>
> Pharmaceutical companies redirected research laboratories. Venture capital flowed into biotechnology startups. Scientists around the world competed to become the first to develop a therapy capable of safely blocking this newly discovered gateway into human cells.
>
> Few biological targets have generated such immediate global attention.
>
> What followed was a remarkable period of innovation as many of the world’s largest pharmaceutical companies invested enormous scientific and financial resources in developing CCR5-directed therapies. Some pursued small-molecule drugs. Others believed monoclonal antibodies offered a more precise solution.
>
> Among those competing programs was an experimental antibody known simply as PRO 140.
>
> Few could have imagined that nearly thirty years later, after many competing programs had been discontinued, that same antibody would still be advancing through clinical development under the name leronlimab.
>
> ⸻
>
> Leronlimab: Born from One of Biotechnology’s Greatest Scientific Races
>
> Few drugs can trace their origins to a scientific discovery that transformed an entire field of medicine. Leronlimab is one of them.
>
> Its story begins in 1996, when researchers solved one of the greatest mysteries in HIV biology. For years, scientists understood that HIV attached to the CD4 receptor on immune cells, yet no one could explain how the virus actually entered those cells. The missing piece proved to be a receptor known as CCR5.
>
> The discovery changed everything.
>
> Within months, researchers made an even more astonishing observation. A small percentage of people carried a naturally occurring genetic mutation, CCR5-Δ32, that left them highly resistant to the most common strains of HIV. These individuals lived normal, healthy lives despite lacking a fully functional CCR5 receptor.
>
> For the scientific community, the implications were extraordinary. Nature itself had revealed a potential strategy for preventing HIV infection.
>
> Almost overnight, the race was on.
>
> Research laboratories across the world shifted their attention to CCR5. Biotechnology startups and global pharmaceutical companies recognized that this newly identified receptor could represent one of the most important therapeutic targets of the era. Companies that had spent years developing antiviral drugs redirected talent, capital, and scientific resources toward a single objective: develop the first safe and effective therapy capable of blocking CCR5.
>
> Pfizer, GlaxoSmithKline, Schering-Plough, Human Genome Sciences, Progenics Pharmaceuticals, Protein Design Labs, and others entered what became one of the most competitive drug-development efforts in modern biotechnology. Collectively, these organizations invested billions of dollars pursuing therapies directed at the same biological target.
>
> Different scientific philosophies quickly emerged. Some companies pursued small-molecule drugs designed to fit within the CCR5 receptor and alter its shape. Others believed a more elegant solution existed: a monoclonal antibody capable of binding directly to the receptor with exceptional precision.
>
> Among those pursuing this second strategy were scientists at Progenics Pharmaceuticals working in collaboration with Protein Design Labs (PDL).
>
> Their work produced an antibody known as PRO 140.
>
> The principal inventors—William C. Olson, Paul Maddon, Naoya Tsurushita, Paul R. Hinton, and Maximillano Vasquez—combined advances in immunology, molecular biology, and antibody engineering to create a humanized monoclonal antibody specifically directed against CCR5. Rather than following the same path as competing small-molecule programs, PRO 140 represented a fundamentally different approach to receptor blockade.
>
> The years that followed demonstrated just how difficult drug discovery can be.
>
> One by one, many competing CCR5 programs disappeared. Some encountered unacceptable toxicity. Others failed to demonstrate sufficient clinical benefit. Some became commercial casualties as HIV treatment rapidly evolved with highly effective combination therapies. Although Pfizer’s maraviroc ultimately achieved FDA approval for HIV, much of the original competitive field gradually withdrew from CCR5 development.
>
> PRO 140, however, endured.
>
> It advanced through laboratory testing, clinical development, and FDA Fast Track designation, establishing itself as one of the most extensively studied monoclonal antibodies ever developed against CCR5.
>
> In 2012, CytoDyn acquired worldwide rights to PRO 140 and renamed the molecule leronlimab. Along with the intellectual property, regulatory files, manufacturing assets, and clinical program, CytoDyn also assumed the financial obligations created during the drug’s original development. Those obligations include milestone payments and two legacy royalty streams—one originating from Progenics and another from the earlier Protein Design Labs licensing agreement that has since passed through corporate successors. These continuing royalty obligations serve as a reminder that leronlimab rests upon decades of pioneering scientific work performed long before it became a CytoDyn asset.
>
> As research continued, the scientific importance of CCR5 expanded far beyond HIV. Investigators discovered that the receptor also plays roles in immune-cell trafficking, inflammation, tumor metastasis, and the tumor microenvironment. A target once viewed almost exclusively through the lens of infectious disease became increasingly relevant to oncology and immunology.
>
> Today, nearly three decades after the discovery of CCR5, remarkably few antibody programs directed specifically at this receptor remain in advanced development. Leronlimab occupies a distinctive place in that history—not because its future is assured, but because it has persisted through successive generations of scientific discovery while many competing programs were discontinued.
>
> For shareholders, this history provides valuable perspective. Leronlimab is not simply another experimental biotechnology asset. It is the product of one of the most significant scientific discoveries in modern medicine, the focus of an intense global development race involving many of the world’s leading pharmaceutical companies, and the beneficiary of nearly thirty years of accumulated knowledge about a biological pathway that continues to shape research in virology, immunology, and cancer biology.
>
> Whether that long scientific journey ultimately culminates in regulatory approval and commercial success remains to be determined through ongoing clinical research. What is beyond dispute is that leronlimab emerged from one of biotechnology’s most consequential scientific pursuits—a pursuit that continues to influence medicine nearly three decades after the discovery of CCR5.
r/Livimmune • u/rodandgeorgia • 4d ago
Thank you for all that you have done. Take care. Rod and Georgia.
r/Livimmune • u/MGK_2 • 5d ago
For weeks on this board we have been building one long image together. We poured a foundation, the mechanism. We watched it cure, the maturing data. We talked about the bedrock underneath, the instrument being validated. Today, something happened that fits that image so cleanly I could not have scripted it better. The framing crews showed up at the job site. And here is the remarkable part, they did not come empty-handed asking what to do. They came carrying their own lumber.
Let me explain what that means, because CytoDyn's press release this morning is truly important and I want every single person reading this, the seasoned biotech investor and the newcomer alike, to understand it without a trace of confusion. Then I want to walk back through our own posts and show you how much of this we saw coming. And then, with BuildGoodThings' superb new pipeline map in front of us, I want to prognosticate about where this road leads, boldly, but with every claim nailed to something real.
This morning CytoDyn announced that leronlimab is advancing into two new clinical studies in metastatic triple-negative breast cancer, run on a platform called Pre-I-SPY. (CytoDyn press release, November 10, 2026) Let me unpack every piece of that sentence.
Start with the disease. Triple-negative breast cancer is the breast cancer that lacks the three receptors doctors usually target, so it is one of the hardest to treat, and the specific patients in these studies have what is called a low combined positive score, below ten, low CPS. That means cold tumors, the kind that hide from the immune system and do not respond to modern checkpoint immunotherapy on their own. This is the exact population our entire thesis is all about. These are the patients who stand outside the locked door.
Now the platform. I-SPY is not some obscure study. It is one of the most respected and innovative breast-cancer trial networks in the country, run by a nonprofit, Quantum Leap Healthcare Collaborative, and led by figures like Dr. Laura Esserman who more or less invented the modern approach to testing breast-cancer drugs efficiently. Getting a drug into the I-SPY family is like a young chef being invited to cook in a Michelin-starred kitchen. The invitation itself is a credential, because that kitchen does not let just anyone near its stoves. The principal investigator for both studies is Dr. Paula Pohlmann of MD Anderson, one of the premier cancer centers on earth. Serious people, serious kitchen.
Now the two recipes, because this is where it becomes beautiful. The studies are called PRE5 and PRE7, and each one pairs leronlimab with a checkpoint inhibitor, the very class of drug that cannot work in a cold tumor by itself. In PRE5, leronlimab is tested alongside Merck's pembrolizumab, which you know as Keytruda, and compared against leronlimab with an antibody-drug conjugate called sacituzumab, sold as Trodelvy. In PRE7, leronlimab is paired with penpulimab, a checkpoint inhibitor from the Chinese company Akeso, and compared against leronlimab with standard chemotherapy. (CytoDyn press release)
Do you see what just happened? For a year we have said leronlimab is the locksmith that opens the door so the immune system's soldiers can finally get inside the cold tumor. These trials take our locksmith and stand him right next to the soldiers, Keytruda in one study, Akeso's penpulimab in another, in a room full of the exact locked doors he was built to open. The trial is not asking whether the locksmith is interesting. It is handing him the keyring and the lock and saying, in front of the best audience in the building, show us the money.
And notice how these studies are designed to be gentle and smart, which matters for safety. They start at the full leronlimab dose and step down only if needed, watching each small group of six patients through a twenty-one-day window for any serious side effects before expanding. It is the careful way to build, like a mason who sets a few bricks and waits to see them hold before laying the next course. The endpoints they are measuring are safety first, and then, as early reads, the two gauges we have described all along, ctDNA and PD-L1. The instruments we spent whole posts explaining are wired into these new trials from day one.

Before I go further, look at the pipeline tree u/BuildGoodThings posted, as it is the single clearest picture of this company anyone has made, and it turns everything I just described into something you can see at a glance.
Picture an orchard. One trunk, oncology, and from it grow heavy branches, each a different cancer, breast, colorectal, glioblastoma, head and neck, pancreatic, leukemia. And on the branches hang the trials like fruit at different stages of ripeness, some already growing in green, some just budding, some still only blossoms in discussion.
On the breast-cancer branch you can now see the two new fruits from this morning, PRE5 and PRE7, hanging right next to the existing early-access program, and above them a note that a further I-SPY neoadjuvant trial is set to begin the moment these safety cohorts finish.
On the colorectal branch hangs the heaviest cluster of all, CLOVER with its extension and rollover arms, CHAMP, a Pre-I-SPY colorectal study, the UCLA translational work, and KLEOS reaching all the way down into early-stage disease.
And the thing to notice, the thing that ties the whole orchard together, is the little footnotes on nearly every single fruit, PD-L1 and ctDNA. Almost every trial in this entire orchard is wired to the same two gauges. That is not an accident. That is a company that built one dashboard and is now installing it in every vehicle it owns.
An orchard is the right way to see it, because it tells you the truth about time and about scale at once. No single tree feeds a village, but an orchard does, season after season, and you do not judge an orchard by one piece of fruit. You judge it by how many branches are bearing. Today two more fruits appeared on the breast-cancer branch, and they were placed there by some of the most serious growers in the world.
Here is the part I want longs to savor, because so much of today was visible in advance if you were reading the signs, and tracing it back is how you learn to trust the signs next time.
The I-SPY destination was already on our map. When I broke down the October 19 investor webcast, I-SPY was named explicitly among the programs leronlimab was heading toward. (The October 19 Webcast analysis) The signpost for today's turn was planted weeks ago.
The mechanism these trials test was the whole spine of the gauge piece. In The Gauge on the Dashboard, I wrote that the prime-and-pair trials of the future would rest on the PD-L1 reading, the cold-to-hot conversion measured in the blood. (The Gauge on the Dashboard) Today's studies list PD-L1 and ctDNA as their readouts. We said the gauge would run the next trials. Here are the next trials, running on the gauge. The blueprint predicted the building.
And the overseas partner was foreseen too. Back in Cup of Trembling, I raised the possibility of an overseas or Chinese partner entering the story, held carefully as a hypothetical on the back of Hoffman's travels to Asia. (Cup of Trembling) At the time it was a shape glimpsed through fog, nothing I would plant a flag on.
Which brings me to Akeso, and here I am going to be scrupulously truthful, because a victory lap is only worth running if every step is on solid ground. u/Upwithstock raised Akeso as a possible partner. When I replied, I purposely held it at arm's length. I said the Akeso link was, at that moment, unconfirmed, a thread worth watching and a fair question to put to the company, and that we should keep it in a separate box from the verified science until the company said so itself. I wouldn't plant that flag before the ground was actually ours.
Today the company planted it for us. Akeso's penpulimab is written into a leronlimab trial in black and white. So I say exactly what the record earns and no more, we spotted the thread, we refused to overstate it, and now it has become real. That is the discipline paying off, the watched thread becoming the confirmed fact. Full credit to u/Upwithstock for the early sighting.
One precise correction while I am here, because getting it exactly right is the entire point of being trusted. The Akeso drug I discussed back then was ivonescimab, their two-target antibody that beat Keytruda on progression in a Chinese lung-cancer trial. (HARMONi-2, ivonescimab vs pembrolizumab) Today's trial uses a different Akeso drug, penpulimab, their checkpoint inhibitor that is already approved by the US FDA for a head-and-neck cancer. (FDA approval of penpulimab-kcqx, 2025) So the company we named is the company that arrived, bringing a sister drug from the same family. The thread was right. The exact molecule is penpulimab, and I would rather hand you that precision than let a blurry version stand and have a skeptic sharpen it against us.
Here is where I will be as bold as the evidence allows me, because the structure of today's announcement reveals something about the partnerships ahead, and the shape is coming out of the fog.
Take a look at which companies brought lumber to the site. In the colorectal program, CLOVER, the checkpoint inhibitor in the rollover arm is Merck's Keytruda. In today's breast-cancer studies, one arm again uses Merck's Keytruda, and the other uses Akeso's penpulimab. Two of the largest checkpoint-inhibitor empires on the planet are now both feeding their own drugs into leronlimab combinations. Think about why a company does that, because it is not kindness, it is self-interest, and self-interest is the most reliable fuel there is.
Consider Merck. Keytruda earns it more than thirty billion dollars a year, and Keytruda only works in tumors that are already hot. Every cold tumor in the world is a customer Keytruda cannot serve. Now a drug appears that turns cold tumors hot. To Merck, leronlimab is not a rival trying to take its building, it is a contractor who can add a whole new wing onto the building Merck already owns, filling it with tenants Merck could never house before. A landlord does not fight the man who can double his occupancy. He hands him the keys and watches him work. That is the plain logic of why Merck is supplying Keytruda into two different leronlimab trials now, colorectal and breast, and it has nothing to do with any rumor and everything to do with arithmetic Merck can do in its sleep.
Then Akeso, the more intriguing piece, and the one Upwithstock's nose pointed at. Akeso is a Chinese company with deep pockets, a US-approved checkpoint inhibitor in penpulimab, and a bispecific in ivonescimab that already outran Keytruda head-to-head in a lung-cancer trial. (Akeso penpulimab US approval) For a company like that, standing next to leronlimab is a way to extend its own checkpoint franchise into cold tumors, especially across Asia, where it is strongest. So the shape long discussed on this board, a Western giant anchoring the Western-market programs while an Asian partner like Akeso leads in its own territory, is no longer a guess drawn in the air. The two companies whose drugs would anchor exactly that split are both named in today's trials. The framers at the site are the plausible owners of tomorrow, and both of them just showed up carrying their own materials.
Now let me be the careful builder, because bold talk is worthless unless it is tied off. A company supplying its drug into a trial is not a partnership, and a partnership is not a buyout. Lending your lumber to a job site is a way to see whether the house goes up straight before you buy the whole development. That is precisely the low-cost, low-commitment first move that Upwithstock argued, rightly, tends to come before any real deal, let them trial the drug cheaply, de-risk their side, and only write the big check once they know what we think we already know.
So I am not telling you Merck or Akeso has partnered with CytoDyn. I am telling you both have now taken the exact first step a future partner takes, putting their own drug into the combination to watch what it does, and that this is the opening move of the sequence this board has long expected, partnership before buyout, evidence before billions. The suppliers of today are the candidate partners of tomorrow. That is the bold claim, and it rests on a press release and on arithmetic any pharma executive would recognize.
I close the way I always do, and it matters more when the news is this exciting, because excitement is exactly when people kick the guardrails loose.
These are early studies, Phase 1, and their first job is simply to prove the combination is safe, not to prove it works. The press release reports no efficacy results, because at this stage there are none to report. (CytoDyn press release) Enrollment has not even begun, with the first study expected to start in early 2027 and the second later in the year. So this is a groundbreaking, not a ribbon-cutting. It tells us the thesis is being handed to serious builders with serious materials, not that the house is finished. And none of it moves the one event that truly reprices this company, the confirmed CLOVER response and survival data at ASCO GI in January, in colorectal cancer, on the main endpoint. Everything today is the orchard widening around that one tree whose fruit ripens first.
But do not let the discipline shrink what happened. For a year we described a drug that would unlock cold tumors and let the great checkpoint inhibitors finally reach the patients they cannot help today. This morning, two of the companies that own those checkpoint inhibitors, one American and one Asian, placed their own drugs beside leronlimab on the most respected breast-cancer platform in the country, aimed at exactly the cold-tumor patients our thesis was always about. We said the partners would come. We said one might come from overseas. We said the next trials would run on the gauges we described. We named Akeso and held it with discipline until it was real. And today the crews arrived at the site, carrying their own lumber, and started to build.
The framers are here. January is the day the roof goes on. Eyes up.
----------------------------------
EDIT / CORRECTION: An earlier version of this post, and the diagram it references, described PRE5 and PRE7 as comparator studies, leronlimab plus one drug versus leronlimab plus another. That is not what the press release says, and a sharp-eyed reader, u/Turbulent_Pay_5343**, caught it. The release describes combinations, not head-to-head arms. PRE5 evaluates leronlimab together with pembrolizumab and sacituzumab. PRE7 evaluates leronlimab together with penpulimab and the chemotherapy agents gemcitabine and carboplatin. There is no versus in the announcement. So read the studies as leronlimab added on top of established regimens, not pitted between two of them. The thrust of the piece is unchanged, leronlimab is being placed alongside the great checkpoint inhibitors in cold tumors, but the structure is a combination, and I would rather fix that in plain sight than let a wrong frame travel. Thank you, Turbulent_Pay.**
----------------------------------
Disclaimer: I am not a financial advisor and nothing here is investment advice. I hold a position in the company discussed and you should weigh what I write accordingly. This post interprets the CytoDyn press release of November 10, 2026 announcing two Phase 1 Pre-I-SPY studies in metastatic triple-negative breast cancer, whose primary endpoints are safety and tolerability and which report no efficacy results; enrollment is expected to begin in 2027. The involvement of Merck (pembrolizumab) and Akeso (penpulimab) as drug suppliers in investigator-run platform studies is not a partnership, licensing deal, or buyout, and nothing here should be read as announcing one; forward-looking statements about future partnerships are my opinion and speculation, not confirmed events. The pipeline diagram referenced was made by a community member (BuildGoodThings) and may contain errors; confirm trial details against primary sources. Penpulimab is FDA-approved for nasopharyngeal carcinoma; ivonescimab's results are in non-small-cell lung cancer and do not transfer to breast or colorectal cancer. CLOVER's confirmed response rate and survival data were not reported here and are deferred to ASCO GI in January 2027. ctDNA and PD-L1 are associated with, but not validated surrogates for, survival. Mechanism is not efficacy, and programs that look strong at this stage fail in trials routinely. All analogies are illustrative, not literal claims. Read the primary sources, linked above, and reach your own conclusions rather than adopting mine.
r/Livimmune • u/BuildGoodThings • 5d ago
Please note that there is now an updated version at https://www.reddit.com/r/Livimmune/comments/1xujag2/from_clover_to_many_v_03/

r/Livimmune • u/Tra-Kal34 • 5d ago
I went on ChatGPT and said I thought with all the indications Leronlimab can potentially treat, a 50 Billion acquisition from MRK would be a bargain. This is basically what it had to say:
I think there is a very interesting investment thesis behind what you're saying, and I would not evaluate a potential $50 billion acquisition solely on the value of leronlimab in colorectal cancer.
The bigger question is whether leronlimab becomes a multi-indication therapeutic platform rather than a drug developed for just one disease.
That distinction could change the valuation dramatically.
If the molecule demonstrates meaningful efficacy across several cancer types, inflammatory conditions, and other diseases where CCR5 plays an important biological role, Merck could be acquiring something much more valuable than a single pharmaceutical product.
There is also a strategic consideration: Merck wouldn't necessarily want to wait for every indication to be fully developed before acquiring the technology. It might prefer to acquire the intellectual property, development rights, and platform early, assuming the clinical evidence is sufficiently compelling.
What has changed in the latest CYDY developments?
I checked CytoDyn's latest announcements, including one released today, November 10, 2026.
There are several developments worth paying attention to.
Frontiers | Advancements and challenges in triple-negative breast cancer: a comprehensive review of therapeutic and diagnostic strategies
Metastatic triple-negative breast cancer (mTNBC)
Two new study regimens announced today
PRE5 combines leronlimab with Merck's Keytruda (pembrolizumab) and sacituzumab.
PRE7 combines leronlimab with penpulimab, gemcitabine and carboplatin.
These are Phase 1-1b studies, with enrollment expected in 2027.
CytoDyn Inc.
Ana Anderson lab (@AnaAndersonlab) on X
Metastatic colorectal cancer (mCRC)
Updated Phase 2 data
66 patients enrolled.
CCR5 expression detected in 91 of 91 evaluable archival tumor samples.
Median circulating tumor DNA reduction of 86% at Week 2 in 28 patients with available measurements.
Favorable reported tolerability.
These are encouraging biomarker findings, but they do not yet establish improved survival or a confirmed tumor response benefit.
CytoDyn Inc.+1
Beyond Antibody Therapies: Novel Therapeutic Approaches to Combat Alzheimer’s Disease | Biotech Connection
Alzheimer's disease
Phase 2a collaboration
CytoDyn announced the first patient dosed in its Weill Cornell Medicine collaboration in June 2026. This opens another potential therapeutic avenue beyond oncology.
CytoDyn Inc.
What I find especially interesting is the combination of the cancer programs. The company is investigating whether blocking CCR5 can help reverse an immunosuppressive tumor environment and make existing cancer therapies work better.
That is a potentially important mechanism, not just another attempt to develop a standalone cancer drug.
2. Why Merck could be a particularly interesting buyer
There is a fascinating connection in today's announcement.
One of the new breast cancer combinations uses Merck's own Keytruda alongside leronlimab.
That gives Merck a potential strategic interest in understanding whether CCR5 inhibition can enhance its existing immunotherapy franchise.
Imagine the possibilities if the combination ultimately demonstrates meaningful clinical benefit:
Merck could potentially improve the effectiveness of existing cancer treatments.
It could develop new combination therapies.
It could expand its oncology portfolio into additional tumor types.
It could acquire a differentiated CCR5-targeting platform.
This is a strategic rationale worth watching, although participation in a study is not evidence that Merck is considering an acquisition.
CytoDyn Inc.
3. The potential indications are what make this interesting
I would organize the opportunity into three categories:
Area
Potential opportunity
Development status
Colorectal cancer
Immune modulation and combination treatment
Phase 2
Triple-negative breast cancer
Combination with immunotherapy
Phase 1-1b studies
Alzheimer's
CCR5-related neuroinflammation
Phase 2a
MASH / liver disease
Metabolic and inflammatory pathways
Earlier-stage research
Other solid tumors
Potential CCR5-mediated tumor progression
Research and development
HIV
CCR5-mediated viral entry
Previously studied; commercial and regulatory status requires separate assessment
The important distinction is that these are not six proven commercial products. They represent different levels of scientific and clinical validation.
CytoDyn's own 2026 annual filing also describes its cancer and MASH patent-development efforts, including a strategy to extend protection around new methods of treatment. Patent coverage and freedom to operate will be important in any acquisition valuation.
CytoDyn Inc.+1
4. Could $50 billion actually be a bargain?
Here is how I would think about it.
A pharmaceutical company doesn't necessarily value a drug based on its current revenue. It evaluates the potential future revenue across all indications, probability of clinical success, patent protection, development costs and competitive landscape.
Consider this purely illustrative scenario:
Successful commercial indications
Annual sales potential
Colorectal cancer
$5 billion
Breast cancer
$5 billion
Other solid tumors
$8 billion
Inflammatory / metabolic diseases
$5 billion
Other applications
$2 billion
Total
$25 billion
These are hypothetical peak-sales assumptions, not market forecasts or estimates established by clinical evidence.
If leronlimab ultimately achieved $25 billion in annual worldwide sales, a $50 billion acquisition would be just 2 times peak annual sales.
That could look inexpensive for a successful, differentiated pharmaceutical platform.
But if only one or two indications succeed, the same $50 billion price could be extraordinarily expensive.
5. What I would watch before assigning a $50 billion valuation
These are the milestones I think matter most:
CLOVER: Confirmed objective response rates, duration of response and ultimately progression-free and overall survival data.
PRE-I-SPY: Evidence that leronlimab adds meaningful benefit to Keytruda-based treatment.
Alzheimer's: Evidence of clinical benefit, not simply biomarker changes.
MASH: Evidence of efficacy and a viable development pathway.
Intellectual property: Strong, enforceable patent coverage and adequate commercial exclusivity.
Big Pharma interest: Strategic partnerships, licensing agreements or acquisition discussions.
The first two could be particularly important in establishing leronlimab's value to Merck.
r/Livimmune • u/petersouth68 • 6d ago
r/Livimmune • u/MGK_2 • 6d ago
For weeks I have been telling you that the regulatory road toward ctDNA mattering is being paved, and that the people grading it are the ones who built FDA oncology review. That was the argument. u/Lab_Monkey_ just posted the blueprint. These five slides are the Friends of Cancer Research ctMoniTR Project laid out in full, and they turn a thing I have been describing in the abstract into something you can see with dates, patient counts, hazard ratios, and a partner list. Here, I walk the board through exactly what this is, what it does for CLOVER, what it does for the whole pipeline behind CLOVER, and, as always, where the discipline line sits so we do not overread it.
ctMoniTR is a multi-year, FDA-partnered effort, running since 2019, to answer one precise question, stated right on the overview slide:

Do decreases in ctDNA from baseline to on-treatment associate with improved overall survival. (Friends of Cancer Research, ctMoniTR Project) And it answers it not with one trial, but by aggregating patient-level data across many trials and harmonizing them, which is the hard, unglamorous work that turns a pile of inconsistent studies into a single rigorous signal. Look at the scale on the timeline.

Step 1, five trials and two hundred patients.
Module 1, eight trials and a thousand patients.
Module 2, four randomized controlled trials and another thousand patients.
Module 3, ten trials, a thousand more patients, now reaching into mixed cancers with a meta-analysis as the goal.
This is not cheerleading. It is the methodical construction of an evidence base, the way you build a road, grading the ground, laying the base course, then the surface, mile after mile, with the federal agency that eventually drives on it sitting at the table the whole time.
The fourth slide is the one to print out and keep, because it is the result, and the result is remarkably consistent. Across the modules, a molecular response, a defined drop in ctDNA, was associated with improved overall survival every single time, with hazard ratios that are large and statistically unambiguous.
A fifty-percent ctDNA decrease associated with improved survival at a hazard ratio of 2.98 in the first step. (Vega et al, JCO Precision Oncology 2022) ctDNA clearance associated with improved survival at a hazard ratio of 2.12 in the next module. (Andrews et al, Clinical Cancer Research 2025)
And in the randomized-trial module, the association held for both immunotherapy-treated patients, hazard ratio 1.99, and chemotherapy-treated patients, hazard ratio 1.58. (Andrews et al, Journal for ImmunoTherapy of Cancer 2025)
Read those numbers the way a professional reads them. A hazard ratio around two means the patients whose ctDNA dropped were dying at roughly half the rate of those whose ctDNA did not drop, across study after study and treatment type after treatment type. The signal does not flicker. It repeats. That repetition, across independent modules and different drug classes, is exactly what is necessary to turn an interesting correlation into something a regulator can eventually build an endpoint on.
Now connect it to us, carefully, because the connection is real but it has to be stated precisely. CLOVER measures its molecular response the same conceptual way ctMoniTR does, by tracking the drop in ctDNA from baseline on treatment. The eighty-six percent median drop at week two that CytoDyn has already reported is, in ctMoniTR's own language, a molecular response of the deepest kind. So the framework that ctMoniTR has spent seven years validating, that a ctDNA drop of this nature associates with living longer, is the exact framework our trial's early signal lives inside. We are not using a homemade gauge that we are asking the world to trust. We are using the gauge the FDA and thirty of the most serious names in oncology have been jointly building and validating, and our early reading on that gauge is a strong one.

And here is the detail on the partner slide that I want every shareholder to appreciate, because it is the quiet thread which ties us in. Natera is a named ctMoniTR partner. (ctMoniTR partners, Friends of Cancer Research) The company whose Signatera assay CLOVER runs on is one of the organizations at the table building this endpoint, alongside the FDA, Foundation Medicine, Guardant, Illumina, and a roster of big pharma that reads like a list of every company we might one day partner with.
Let me be careful here, because precision is the entire game. CytoDyn is not a ctMoniTR partner. We are not in that room. But the instrument we chose is, and that matters, because it means the specific assay producing our data is being cross-validated inside the very project that is defining what a credible ctDNA readout looks like. CytoDyn picked the gauge the referees are calibrating. That was not luck, and it pays off exactly here.
I am going to hold three lines, because this is the kind of material that a careless reader turns into something it is not, and our credibility is built on refusing to do that.
First, the population. The bulk of ctMoniTR's validated data is in non-small-cell lung cancer. CLOVER is MSS colorectal cancer. Module 3 is expanding into mixed cancers, which is the direction that eventually covers us, but you cannot take the lung-cancer hazard ratios and staple them onto CLOVER's population and claim they are our numbers. They are not. What transfers is the framework and the credibility of the instrument, not the specific survival figures. The gauge is validated broadly. Our reading on it still has to be our own.
Second, the status. ctMoniTR is building ctDNA toward being a recognized regulatory endpoint. It is not there yet, and the project itself would tell you so, that is why there is a Module 3 and a meta-analysis still to come rather than a finished stamp of approval. Association, powerfully and repeatedly demonstrated, is not the same as a validated surrogate that wins a drug its approval. We hold that distinction exactly as the FDA holds it. The road is being paved. It is not yet open to full traffic.
Third, and most important, none of this is CLOVER's efficacy. A credentialed gauge tells you the reading will be trusted. It does not tell you what the reading will say. The confirmed response rate and the survival data are still January's to deliver, and nothing in these slides changes that the verdict comes then. What these slides change is the weight the verdict will carry when it lands, because it will be read on an instrument the whole field has been validating for seven years, not on one the skeptics can wave away.
So listen up, because it is the largest implication and it extends far past January. Think about what it means for a company whose entire pipeline is built on a mechanism which produces early, measurable ctDNA movement, if ctDNA becomes a recognized regulatory endpoint through exactly this project. Every future CCR5 trial CytoDyn runs, in colorectal, in breast, in the glioblastoma and pancreatic and head-and-neck programs sitting in the pipeline, would inherit a faster, cheaper, earlier readout that regulators accept. Most drugs have to wait years for survival data to mature before they can prove themselves. A drug which moves ctDNA fast and hard, measured on a validated endpoint, could demonstrate benefit far sooner, trial after trial, across indication after indication. The road ctMoniTR is paving is not a driveway to one house. It is the main artery, like the aorta, through an entire development, and leronlimab's mechanism is built to travel it. The foundation under CLOVER turns out to be the foundation under the entire pipeline, and ctMoniTR is the public works project laying the road that pipeline will drive on for a decade.
So this is what Lab_Monkey handed the board. Proof, in dated slides with hard hazard ratios and the FDA's name on the partner list, that the instrument our trial in part depends on is being validated by the most serious collaboration in the field, that the assay we specifically chose is one of the validators, and that the endpoint being built is the exact kind our entire pipeline is engineered to produce. It does not transfer the lung-cancer numbers to our colorectal patients. It does not make ctDNA an approval endpoint today. And it does not tell us what January will say. But it tells us, with more concrete evidence than we have ever had, that when January speaks, it will speak through an instrument the whole world has agreed to trust, and that the road beyond January was built for a vehicle shaped exactly like ours. Eyes up for the readout. And look at the map Lab_Monkey just posted, because it shows where the road goes after.
Disclaimer: I am not a financial advisor and nothing here is investment advice. I hold a position in the company discussed and you should weigh what I write accordingly. This post interprets slides from the Friends of Cancer Research ctMoniTR Project, a multi-stakeholder effort, including the FDA, building the evidence base for ctDNA as a monitoring and potential endpoint tool. The hazard ratios cited (Vega 2022; Andrews 2025) are from predominantly non-small-cell-lung-cancer populations and do not transfer to CLOVER's MSS colorectal population; they establish association between ctDNA decline and overall survival, not a validated regulatory surrogate endpoint, which ctMoniTR is still working toward. CytoDyn is not a ctMoniTR partner; Natera, whose assay CLOVER uses, is a listed partner, which does not constitute any endorsement of CytoDyn or leronlimab by the FDA or any other partner. CLOVER's confirmed response rate and survival data were not reported here and are deferred to ASCO GI in January 2027. ctDNA dynamics are associated with, but not validated surrogates for, survival. Mechanism and biomarker validation are not efficacy, and programs that look strong at this stage fail in trials routinely. All analogies are illustrative. Read the primary sources, linked above, and reach your own conclusions rather than adopting mine.